CLOs on the Move

NorthStar Medical Radioisotopes

www.northstarnm.com

 
NorthStar® Medical Radioisotopes is a nuclear medicine technology company dedicated to transforming the ways that medical radioisotopes are produced and distributed around the world.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Harrow

Harrow is a growing leader in the ophthalmic healthcare market, providing affordable and accessible medications to eyecare providers and patients. They offer a simple and transparent platform to help ophthalmologists and optometrists better serve patie...

major pharmaceuticals

major pharmaceuticals is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BioBlast Pharma

BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The BioBlast platforms are based on deep understandings of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.

UltraFiltronics Corp

UltraFiltronics Corp is a Randolph, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.